NEWS

Two teams independently come up with a way to avert CRS in CAR … – Medical Xpress

European BiotechnologyTwo teams independently come up with a way to avert CRS in CAR …Medical XpressTwo teams of researchers, one working in the U.S., the other in Italy, have come up with new ways to avert cytokine release syndrome (CRS) in leukemia… Continue reading

Tisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDA – ReliaWire

ReliaWireTisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDAReliaWireThe CAR T-cell therapy tisagenlecleucel, marketed as Kymriah, was recently approved by the FDA for adults with certain types of non-Hodgkin lymphoma. This is the second … Continue reading

Tisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDA – ReliaWire

ReliaWireTisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDAReliaWireThe CAR T-cell therapy tisagenlecleucel, marketed as Kymriah, was recently approved by the FDA for adults with certain types of non-Hodgkin lymphoma. This is the second … Continue reading

Monitoring Adverse Effects of Immunotherapy – www.oncnursingnews.com/

Aimmune Therapeutics (AIMT) Announces Data on Terminology Used with Oral Immunotherapy Were Presented at … – StreetInsider.com

Proactive Investors UKAimmune Therapeutics (AIMT) Announces Data on Terminology Used with Oral Immunotherapy Were Presented at …StreetInsider.comAimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentia… Continue reading

The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025 – PR Newswire (press release)

Technology NetworksThe global cancer stem cells market size is expected to reach USD 1.6 billion by 2025PR Newswire (press release)LONDON, May 29, 2018 /PRNewswire/ — Cancer Stem Cells Market Share, Size & Trends Analysis Report By MoA (Stem Cell … Continue reading